Eyenovia Inc.
| NASDAQ: EYEN | Healthcare / Biotechnology / USA |
| 3.19 | +0.0100 | +0.31% | Vol 167 350 | 1Y Perf -51.29% |
| Jul 19th, 2019 16:00 |
| BID | 3.14 | ASK | 3.26 | ||
| Open | 3.15 | Previous Close | 3.18 | ||
| Pre-Market | - | After-Trading | - | ||
| - -% | - -% |
| Target Price | 18.25 | Analyst Rating | Strong Buy 1.00 | |
| Potencial % | 472.10 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12M | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12M | -/-/100 | Income Ranking | — - | |
| Market Cap (mil) | 38 | Earnings Rating | Sell | |
| Price Range Ratio 52wk % | 17.25 | Earnings Date | 13th Aug 2019 |
Today's Price Range 3.013.27 | 52wk Range 2.406.98 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 11.93% | ||
| 1 Month | -30.35% | ||
| 3 Months | -51.07% | ||
| 6 Months | 14.75% | ||
| 1 Year | -51.29% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | - | |||
ROE last 12 Months | -100.49 | |||
Return on Assets (5Y Avg) | - | |||
ROA last 12 Months | -91.87 | |||
Return on Capital (5Y Avg) | - | |||
ROC last 12 Months | -100.49 | |||
Return on invested Capital Q | -40.45 | |||
Return on invested Capital Y | -157.09 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 2.76 | |||
PS Ratio | - | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -2.50 | |||
Cash Flow Per Share | -1.57 | |||
Price to Tangible Book | 2.76 | |||
Book Value per Share | 1.03 | |||
Enterprise Value (in ths.) | 20 038 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 5.70 | |||
Current Ratio | 5.90 | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | - | |||
Interest Coverage | - | |||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | - | |||
EBIT Margin | - | |||
EBITDA Margin | - | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 0 | |||
Revenue per Share | 0.00 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2019 | -0.51 | -0.50 | 1.96 |
| Q04 2018 | -0.43 | -0.60 | -39.53 |
| Q03 2018 | -0.42 | -0.43 | -2.38 |
| Q02 2018 | -0.39 | -0.33 | 15.38 |
| Q01 2018 | -0.39 | -0.45 | -15.38 |
| Q04 2017 | -0.34 | -0.84 | -147.06 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2019 QR | -0.47 | -9.30 | Negative |
| 9/2019 QR | -0.42 | 0.00 | - |
| 12/2019 FY | -1.80 | -5.88 | Negative |
| 12/2020 FY | -1.54 | -1.99 | Negative |
| Next Report Date | 13th Aug 2019 |
| Estimated EPS Next Report | -0.47 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 167 350 |
| Shares Outstanding (in ths.) | 12 054 |
| Trades Count | 479 |
| Dollar Volume | 473 237 |
| Avg. Volume | 174 137 |
| Avg. Weekly Volume | 297 869 |
| Avg. Monthly Volume | 228 707 |
| Avg. Quarterly Volume | 104 644 |
Eyenovia Inc.
Eyenovia Inc is a clinical-stage biopharmaceutical company operating in the US. It is engaged in developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. The pipeline products of the company are MicroProst for chronic angle closure glaucoma, MicroStat for pharmacologic mydriasis, MicroTears for dry eye and MicroPine for myopia.
CEO: Tsontcho Ianchulev
Teplephone: +1 917 289-1117
Address: 295 Madison Avenue, New York 10017, NY, USA
